Different methods such as exposure-adjusted incidence rates and exposure-adjusted event rates are used to report adverse events in rheumatoid arthritis (RA) clinical trials, this study compared different methodologies of reporting in long-term filgotinib integrated safety data. touchIMMUNOLOGY were delighted to speak with Prof Patrick Durez (Cliniques Universitaires Saint-Luc – Université Catholique de Louvain (UCL), Brussels, Belgium) around the aims, design and findings of the study.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘The Use of Exposure-Adjusted Event Rates versus Exposure-Adjusted Incidence Rates in Adverse Event Reporting: Insights from Filgotinib Integrated Safety Data in RA.‘ (Abstract number: 0278) was presented at the ACR Convergence, November 10–14, 2022.
- Could you explain the terms exposure-adjusted incidence rates (EAIRs) and exposure-adjusted event rates (EAERs) in reporting treatment-emergent adverse events in clinical trials? (0:19)
- Which of these is most commonly used in RA studies and how can this affect the outcome evaluation? (1:01)
- What were the aims and design of your study? (1:37)
- What were the findings of the study? (2:06)
- What is the key take-home message for future clinical trial design? (2:40)
Disclosures: Patrick Durez has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Rheumatoid Arthritis
Paul Studenic, ACR 2022: A validation study of the revised ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the methodology and findings of the validation […]
Paul Studenic, ACR 2022: The 2022 revision of the ACR/EULAR remission criteria for rheumatoid arthritis
ACR and EULAR endorsed provisional criteria, both Boolean and index-based, to define remission in rheumatoid arthritis (RA) over 10 years ago, in 2022 a revision of the remission criteria has been made. touchIMMUNOLOGY were delighted to speak with Dr. Paul Studenic (Medical University of Vienna, Vienna, Austria) to discuss the limitations of the Boolean and […]
Kim Lauper, ACR 2022: Safety of JAK-inhibitors in rheumatoid arthritis in a real-world population
The JAK inhibitor (JAKi) tofacitinib was associated with an increased risk of serious adverse events compared to TNF-inhibitors in the treatment of rheumatoid arthritis in the ORAL surveillance study (NCT02092467). In this interview, touchIMMUNOLOGY were delighted to speak with Dr. Kim Lauper (Geneva University Hospitals, Genéve, Switzerland) around her study assessing the safety of JAKis […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!